284 related articles for article (PubMed ID: 26521988)
21. Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.
Karp JE; Garrett-Mayer E; Estey EH; Rudek MA; Smith BD; Greer JM; Drye DM; Mackey K; Dorcy KS; Gore SD; Levis MJ; McDevitt MA; Carraway HE; Pratz KW; Gladstone DE; Showel MM; Othus M; Doyle LA; Wright JJ; Pagel JM
Haematologica; 2012 Nov; 97(11):1736-42. PubMed ID: 22733022
[TBL] [Abstract][Full Text] [Related]
22. Phase I study of alvocidib plus cytarabine/mitoxantrone or cytarabine/daunorubicin for acute myeloid leukemia in Japan.
Ikezoe T; Ando K; Onozawa M; Yamane T; Hosono N; Morita Y; Kiguchi T; Iwasaki H; Miyamoto T; Matsubara K; Sugimoto S; Miyazaki Y; Kizaki M; Akashi K
Cancer Sci; 2022 Dec; 113(12):4258-4266. PubMed ID: 35689544
[TBL] [Abstract][Full Text] [Related]
23. Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.
Tan AR; Swain SM
Semin Oncol; 2002 Jun; 29(3 Suppl 11):77-85. PubMed ID: 12138401
[TBL] [Abstract][Full Text] [Related]
24. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
25. Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Blachly JS; Byrd JC; Grever M
Semin Oncol; 2016 Apr; 43(2):265-73. PubMed ID: 27040705
[TBL] [Abstract][Full Text] [Related]
26. [Flavopiridol, a cyclin-dependent kinase inhibitor].
Lansiaux A; Bailly C
Bull Cancer; 2000 Oct; 87(10):697-701. PubMed ID: 11084532
[No Abstract] [Full Text] [Related]
27. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
Lyle L; Daver N
Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
[TBL] [Abstract][Full Text] [Related]
28. Flavopiridol: the first cyclin-dependent kinase inhibitor in human clinical trials.
Senderowicz AM
Invest New Drugs; 1999; 17(3):313-20. PubMed ID: 10665481
[TBL] [Abstract][Full Text] [Related]
29. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Holkova B; Supko JG; Ames MM; Reid JM; Shapiro GI; Perkins EB; Ramakrishnan V; Tombes MB; Honeycutt C; McGovern RM; Kmieciak M; Shrader E; Wellons MD; Sankala H; Doyle A; Wright J; Roberts JD; Grant S
Clin Cancer Res; 2013 Apr; 19(7):1873-83. PubMed ID: 23515411
[TBL] [Abstract][Full Text] [Related]
30. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias.
Karp JE; Smith BD; Resar LS; Greer JM; Blackford A; Zhao M; Moton-Nelson D; Alino K; Levis MJ; Gore SD; Joseph B; Carraway H; McDevitt MA; Bagain L; Mackey K; Briel J; Doyle LA; Wright JJ; Rudek MA
Blood; 2011 Mar; 117(12):3302-10. PubMed ID: 21239698
[TBL] [Abstract][Full Text] [Related]
31. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia.
Nelson DM; Joseph B; Hillion J; Segal J; Karp JE; Resar LM
Leuk Lymphoma; 2011 Oct; 52(10):1999-2006. PubMed ID: 21728742
[TBL] [Abstract][Full Text] [Related]
32. Sequential treatment with flavopiridol synergistically enhances pyrrolo-1,5-benzoxazepine-induced apoptosis in human chronic myeloid leukaemia cells including those resistant to imatinib treatment.
Bright SA; Campiani G; Deininger MW; Lawler M; Williams DC; Zisterer DM
Biochem Pharmacol; 2010 Jul; 80(1):31-8. PubMed ID: 20206141
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Bible KC; Kaufmann SH
Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
[TBL] [Abstract][Full Text] [Related]
34. Clinical trials referral resource. Flavopiridol.
Colevas D; Blaylock B; Gravell A
Oncology (Williston Park); 2002 Sep; 16(9):1204-5, 1210-2, 1214. PubMed ID: 12380947
[No Abstract] [Full Text] [Related]
35. Hematologic improvement after flavopiridol treatment of pentostatin and rituximab refractory hairy cell leukemia.
Jones JA; Kraut EH; Deam D; Byrd JC; Grever MR
Leuk Lymphoma; 2012 Mar; 53(3):490-1. PubMed ID: 22165992
[No Abstract] [Full Text] [Related]
36. [Therapeutic effect of flavopiridol, a small molecular cyclin-dependent kinase inhibitor, in human ovarian carcinoma].
Song Y; Shen K; Tang PP
Zhonghua Fu Chan Ke Za Zhi; 2007 Nov; 42(11):761-4. PubMed ID: 18307904
[TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
Senderowicz AM
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1229-53. PubMed ID: 12512390
[TBL] [Abstract][Full Text] [Related]
38. Emerging cell cycle inhibitors for acute myeloid leukemia.
Abou Zahr A; Borthakur G
Expert Opin Emerg Drugs; 2017 Jun; 22(2):137-148. PubMed ID: 28506135
[TBL] [Abstract][Full Text] [Related]
39. Emerging drug profile: cyclin-dependent kinase inhibitors.
Blachly JS; Byrd JC
Leuk Lymphoma; 2013 Oct; 54(10):2133-43. PubMed ID: 23488658
[TBL] [Abstract][Full Text] [Related]
40. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.
Tan AR; Yang X; Berman A; Zhai S; Sparreboom A; Parr AL; Chow C; Brahim JS; Steinberg SM; Figg WD; Swain SM
Clin Cancer Res; 2004 Aug; 10(15):5038-47. PubMed ID: 15297405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]